The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TYSABRI natalizumab 300mg/15 mL concentrate for infusion vial (112372)
ARTG Name
TYSABRI natalizumab 300mg/15 mL concentrate for infusion vial
Product name
TYSABRI natalizumab 300mg/15 mL concentrate for infusion vial
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicine
Sponsor
Ingredients
Natalizumab
Licence category
RE
Licence status
A
Summary
Product Information
Consumer Medicine Information